公开(公告)号：US20200239593A1

公开(公告)日：2020-07-30

申请号：US16733376

申请日：2020-01-03

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Hergen SPITS ,  Tim BEAUMONT ,  Marijn Aletta GILLISSEN ,  Adrianus Quirinus BAKKER ,  Mette Deborah HAZENBERG ,  Martijn KEDDE

IPC: C07K16/30 ,  C07K16/06 ,  A61K47/68 ,  C07K16/40 ,  C12P21/00 ,  G01N33/574

Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

公开(公告)号：US20170313766A1

公开(公告)日：2017-11-02

申请号：US15645399

申请日：2017-07-10

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Hergen SPITS ,  Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Arjen Quirinus BAKKER

IPC: C07K16/10 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983

Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.

公开(公告)号：US20170313764A1

公开(公告)日：2017-11-02

申请号：US15508570

申请日：2015-09-07

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Tim BEAUMONT ,  Sabrina Julia Louisa MERAT ,  Cornelia Johanna SCHINKEL ,  Richard MOLENKAMP

IPC: C07K16/10

CPC classification number: C07K16/109 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for hepatitis C virus (HCV). The invention further relates to the use of such antibodies for diagnosis, treatment and prevention of HCV infection.

公开(公告)号：US20170009205A1

公开(公告)日：2017-01-12

申请号：US15106991

申请日：2014-12-24

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Pauline Maria Wilhelmina VAN HELDEN ,  Mark Jeroen KWAKKENBOS ,  Hergen SPITS ,  Tim BEAUMONT

IPC: C12N5/0781 ,  C07K16/10 ,  C12P21/00 ,  C07K16/00

CPC classification number: C12N5/0635 ,  C07K16/00 ,  C07K16/1018 ,  C07K2317/14 ,  C12N15/86 ,  C12N2510/00 ,  C12N2510/02 ,  C12N2510/04 ,  C12N2740/13045 ,  C12N2810/6054 ,  C12P21/005

Abstract: The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.

Abstract translation: 本发明提供用于生产具有短加倍时间的改进的离体B细胞培养物的方法和方法。

公开(公告)号：US20160194382A1

公开(公告)日：2016-07-07

申请号：US15048339

申请日：2016-02-19

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Hergen SPITS ,  Adrianus Quirinus BAKKER

IPC: C07K16/10

CPC classification number: C07K16/1027 ,  C07K16/00 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.

Abstract translation: 本发明提供用于调节抗体产生浆细胞样B细胞中体细胞超突变的发生的方法和方法。

公开(公告)号：US20170067880A1

公开(公告)日：2017-03-09

申请号：US15246301

申请日：2016-08-24

Applicant: Genentech, Inc. ,  AIMM Therapeutics B.V.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: G01N33/50 ,  C07K16/12 ,  G01N33/68

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。 提供了完全人类的结合化合物，可在人类个体中实现治疗应用。

公开(公告)号：US20160326261A1

公开(公告)日：2016-11-10

申请号：US15105076

申请日：2014-12-17

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Hergen SPITS ,  Tim BEAUMONT ,  Marijn Aletta GILLISSEN ,  Adrianus Quirinus BAKKER ,  Mette Deborah Hazenberg

IPC: C07K16/30 ,  G01N33/574 ,  C12P21/00 ,  A61K47/48 ,  C07K16/40

Abstract: The invention provides human AML-specific binding compounds that are able to bind a cell surface component of AML cells. Therapeutic uses of binding compounds against AML are also provided.

Abstract translation: 本发明提供能够结合AML细胞的细胞表面组分的人类AML特异性结合化合物。 还提供了针对AML的结合化合物的治疗用途。

公开(公告)号：US20160096881A1

公开(公告)日：2016-04-07

申请号：US14956919

申请日：2015-12-02

Applicant: AIMM THERAPEUTICS B.V.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Hergen SPITS ,  Adrianus Quirinus BAKKER ,  Koen WAGNER

IPC: C07K16/10

CPC classification number: C07K16/1018 ,  C07K14/4703 ,  C07K14/4747 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92

Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.

Abstract translation: 本发明提供了用于产生针对感兴趣的抗原（通常是稳定的B细胞培养物）的高亲和力抗体的方法和方法。

公开(公告)号：US20140235828A1

公开(公告)日：2014-08-21

申请号：US14103715

申请日：2013-12-11

Applicant: AIMM THERAPEUTICS B.V. ,  Genentech, Inc

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: C07K16/12

CPC classification number: G01N33/5091 ,  C07K16/1271 ,  C07K16/1278 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2469/10 ,  G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。 提供了完全人类的结合化合物，可在人类个体中实现治疗应用。

公开(公告)号：US20180292391A1

公开(公告)日：2018-10-11

申请号：US15900589

申请日：2018-02-20

Applicant: Genentech, Inc. ,  AIMM Therapeutics B.V.

Inventor： Tim BEAUMONT ,  Mark Jeroen KWAKKENBOS ,  Eric J. BROWN ,  John Hiroshi MORISAKI ,  Wouter L.W. HAZENBOS ,  Sanjeev MARIATHASAN ,  Kimberly KAJIHARA ,  Yi XIA

IPC: G01N33/50 ,  G01N33/68 ,  C07K16/12

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.